GlassScriptPhysician profile
William Glenton Buxton
NPI 1669495149
$6,053.21
in general payments reported to CMS, 2019-2025
32 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $324 · 2021: $312 · 2022: $1,901 · 2023: $655 · 2024: $689 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $2,129.71 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $976.24 | 2023-2025 | Zilbrysq, Rystiggo |
| Csl Behring | $408.92 | 2019-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $386.18 | 2019-2025 | Nuplazid |
| Abbvie INC. | $253.82 | 2021-2025 | Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $230.30 | 2022-2025 | Hyqvia, Gammagard |
| Alexion Pharmaceuticals, INC. | $226.04 | 2019-2025 | Ultomiris |
| Akcea Therapeutics, INC. | $166.97 | 2019-2020 | |
| Lilly USA, LLC | $138.11 | 2022-2024 | Amyvid, Kisunla |
| Biogen, INC. | $136.03 | 2021-2025 | Leqembi |
| Catalyst Pharmaceuticals, INC. | $122.24 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $117.11 | 2021-2025 | Crexont, Rytary |
| Lundbeck LLC | $114.07 | 2020-2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $89.21 | 2019 | |
| Neurocrine Biosciences, INC. | $74.23 | 2024-2025 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $68.05 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $52.72 | 2024-2025 | Dysport |
| Janssen Pharmaceuticals, INC | $46.71 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.57 | 2020-2021 | |
| Medtronic, INC. | $36.67 | 2021 | |
| Grifols USA, LLC | $25.09 | 2019 | |
| Eisai INC. | $24.91 | 2024 | |
| Ge Healthcare | $24.73 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.97 | 2025 | Wainua |
| Abbott Laboratories | $23.07 | 2025 | Infinity |
| Tanabe Pharma America, INC. | $20.68 | 2025 | Radicava |
| Merz Pharmaceuticals, LLC | $18.68 | 2021 | |
| Zyla Life Sciences, INC. | $17.69 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.68 | 2021 | |
| Acorda Therapeutics, INC | $15.98 | 2021 | |
| Amgen INC. | $15.67 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Buxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.